Keros Therapeutics Repurchase Agreement with Pontifax Parties

On October 15, 2025, Keros Therapeutics, Inc. entered into a Stock Purchase Agreement with the Pontifax Parties, resulting in the repurchase of 4,787,331 shares of Common Stock at $17.75 per share, totaling $84,975,125.25. This transaction led to the Pontifax Parties no longer being beneficial owners of more than 5% of the outstanding shares. Additionally, Tomer Kariv and Ran Nussbaum, affiliates of the Pontifax Parties, resigned from Keros Therapeutics' board of directors. The agreement includes standstill restrictions, voting commitments, and mutual non-disparagement obligations during the Standstill Period.